[A22-50] Brolucizumab (visual impairment due to diabetic macular oedema) – Benefit assessment according to §35a Social Code Book V
Last updated 01.08.2022
Project no.:
A22-50
Commission:
Commission awarded on 27.04.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Indication:
Visual impairment due to diabetic macular oedema in adults
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-23 | Brolucizumab (neovascular age-related macular degeneration) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-101 | Brolucizumab (neovascular age-related macular degeneration) – Benefit assessment according to §35a Social Code Book V (expiry of the decision) | Commission completed |